Evidence map›Paper›PMID 39509458›Full record

ArticlePLoS genetics2024

Contribution of p53-dependent and -independent mechanisms to upregulation of p21 in Fanconi anemia.

Xavier Renaudin, Baraah Al Ahmad Nachar, Benedetta Mancini, Anna Gueiderikh, Noémie Louis-Joseph, Frédérique Maczkowiak-Chartois, Filippo Rosselli

Abstract read
In one paragraph

Article in PLoS genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xavier RenaudinCNRS UMR9019, Université Paris-Saclay, Gustave Roussy Institute Cancer Campus, Villejuif, France.ORCID https://orcid.org/0000-0002-2970-6010
Baraah Al Ahmad NacharCNRS UMR9019, Université Paris-Saclay, Gustave Roussy Institute Cancer Campus, Villejuif, France.
Benedetta ManciniCNRS UMR9019, Université Paris-Saclay, Gustave Roussy Institute Cancer Campus, Villejuif, France.
Anna GueiderikhCNRS UMR9019, Université Paris-Saclay, Gustave Roussy Institute Cancer Campus, Villejuif, France.
Noémie Louis-JosephCNRS UMR9019, Université Paris-Saclay, Gustave Roussy Institute Cancer Campus, Villejuif, France.
Frédérique Maczkowiak-ChartoisCNRS UMR9019, Université Paris-Saclay, Gustave Roussy Institute Cancer Campus, Villejuif, France.
Filippo RosselliCNRS UMR9019, Université Paris-Saclay, Gustave Roussy Institute Cancer Campus, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abnormal expression of the cell cycle inhibitor and p53 target CDKN1A/p21 has been associated with paradoxical outcomes, such as hyperproliferation in p53-deficient cancer cells or hypoproliferation that affects hematopoietic stem cell behavior, leading to bone marrow failure (BMF). Notably, p21 is known to be overexpressed in Fanconi anemia (FA), which is a rare syndrome that predisposes patients to BMF and cancer. However, why p21 is overexpressed in FA and how it contributes to the FA phenotype(s) are still poorly understood. Here, we revealed that while the upregulation of p21 is largely dependent on p53, it also depends on the transcription factor microphthalmia (MITF) as well as on its interaction with the nucleolar protein NPM1. Upregulation of p21 expression in FA cells leads to p21 accumulation in the chromatin fraction, p21 immunoprecipitation with PCNA, S-phase lengthening and genetic instability. p21 depletion in FA cells rescues the S-phase abnormalities and reduces their genetic instability. In addition, we observed that reactive oxygen species (ROS) accumulation, another key feature of FA cells, is required to trigger an increase in PCNA/chromatin-associated p21 and to impact replication progression. Therefore, we propose a mechanism by which p21 and ROS cooperate to induce replication abnormalities that fuel genetic instability.

Indexed as

Cyclin-Dependent Kinase Inhibitor p21Fanconi AnemiaNucleophosminReactive Oxygen SpeciesTumor Suppressor Protein p53Up-RegulationChromatinGenomic InstabilityHumansNuclear ProteinsProliferating Cell Nuclear AntigenS PhaseCDKN1A protein, humanChromatinCyclin-Dependent Kinase Inhibitor p21NPM1 protein, humanNuclear ProteinsNucleophosminPCNA protein, humanProliferating Cell Nuclear AntigenReactive Oxygen SpeciesTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID39509458
PMCPMC11575784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.